BioSyent Inc. (CVE:RX – Get Free Report) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of C$14.26 and traded as low as C$13.92. BioSyent shares last traded at C$14.05, with a volume of 22,577 shares changing hands.
BioSyent Price Performance
The stock has a market capitalization of C$159.21 million, a price-to-earnings ratio of 17.92 and a beta of 1.02. The company has a current ratio of 1.89, a quick ratio of 6.91 and a debt-to-equity ratio of 11.66. The company’s 50 day moving average is C$14.26 and its 200 day moving average is C$14.04.
About BioSyent
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Featured Stories
- Five stocks we like better than BioSyent
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
- Capri’s Turnaround Is Taking Shape, But Is the Stock a Buy Yet?
- SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
